-
1.发明公开2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS 有权2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA-DERIVATE ALS FORMYLPEPTIDREZEPTOR-LIKE-1（FPRL-1）-REZEPTORMODULATOREN
公开(公告)号：EP2776403A1
公开(公告)日：2014-09-17
申请号：EP12791050.3
申请日：2012-11-10
申请人： ALLERGAN, INC.
发明人： BEARD, Richard L. , VULIGONDA, Vidyasagar , VU, Thong , DONELLO, John E. , VISWANATH, Veena , GARST, Michael E.
IPC分类号： C07D233/80 , C07D235/02 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , A61P29/00 , A61P27/02 , A61K31/4184 , A61K31/4178 , A61K31/4166
CPC分类号： C07D233/86 , C07D233/80 , C07D235/02 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , C07D471/04 , C07F9/65067
摘要： The present invention relates to novel 2,5-dioxoimidazolidin-l-yl-3- phenylurea derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
-
2.发明公开METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B 审中-公开方法的处理对维甲酸吸引力与CYP26A和CYP26B的选择性抑制剂疾病
公开(公告)号：EP1696899A1
公开(公告)日：2006-09-06
申请号：EP04814113.9
申请日：2004-12-13
申请人： ALLERGAN, INC.
发明人： VASUDEVAN, Jayasree , YANG, Rong , WANG, Liming , LIU, Xiaoxia , TSANG, Kwok, Yin , LI, Ling , TAKEUCHI, Janet, A. , VU, Thong , BEARD, Richard, L. , BHAT, Smita , CHANDRARATNA, Roshantha, A.
IPC分类号： A61K31/19 , A61K31/35 , A61K31/38 , A61K31/192
CPC分类号： A61K31/19 , A61K31/192 , A61K31/35 , A61K31/38
摘要： The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
-
3.发明公开POLYCYCLIC PYRROLIDINE-2,5-DIONE DERIVATIVES AS -FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS 审中-公开多环吡啶-2,5-二氧杂环己烷甲醛脱氢酶-1（FPRL-1）-REZEPTORMODULATOREN
公开(公告)号：EP2731931A1
公开(公告)日：2014-05-21
申请号：EP12735412.4
申请日：2012-07-03
申请人： Allergan, Inc.
发明人： BEARD, Richard L. , VULIGONDA, Vidyasagar , VU, Thong , DONELLO, John E. , VISWANATH, Veena , GARST, Michael E.
IPC分类号： C07D209/96 , A61K31/4015 , A61P27/00 , A61P25/00 , A61P31/00 , A61P17/00 , A61P9/00 , A61P19/00 , C07D401/12
CPC分类号： C07D209/96 , C07D401/12
摘要： The present invention relates to novel polycyclic pyrrolidine-2, 5-dione derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators the N-formyl peptide receptor like-1 (FPRL-1) receptor.
-
4.发明公开DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS 审中-公开二氢萘甲酸钠 - 萘磺酸盐N-甲基哌啶酮类似物-1（FPRL-1）-REZEPTORMODULATOREN
公开(公告)号：EP2686295A1
公开(公告)日：2014-01-22
申请号：EP12708478.8
申请日：2012-03-02
申请人： Allergan, Inc.
发明人： VULIGONDA, Vidyasagar , BEARD, Richard L. , VU, Thong , DONELLO, John E. , VISWANATH, Veena , GARST, Michael E.
IPC分类号： C07C233/59 , A61K31/16 , A61P29/00
CPC分类号： C07C235/84 , C07C233/59 , C07C235/82 , C07C2602/10
摘要： The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
摘要翻译： 本发明涉及新型二氢萘和萘衍生物，其制备方法，含有它们的药物组合物及其作为N-甲酰基肽受体1（FPRL-1）受体调节剂的药物的用途。
-
5.发明授权2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS 有权2,5-二氧代咪唑烷-1-基-3-苯基脲衍生物作为甲酰肽受体样-1（FPRL-1）受体调节剂
公开(公告)号：EP2776403B1
公开(公告)日：2016-09-14
申请号：EP12791050.3
申请日：2012-11-10
申请人： ALLERGAN, INC.
发明人： BEARD, Richard L. , VULIGONDA, Vidyasagar , VU, Thong , DONELLO, John E. , VISWANATH, Veena , GARST, Michael E.
IPC分类号： C07D233/80 , C07D235/02 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , A61P29/00 , A61P27/02 , A61K31/4184 , A61K31/4178 , A61K31/4166
CPC分类号： C07D233/86 , C07D233/80 , C07D235/02 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , C07D471/04 , C07F9/65067
-
公开(公告)号：EP2300456A1
公开(公告)日：2011-03-30
申请号：EP09751286.7
申请日：2009-05-18
申请人： Allergan, Inc.
发明人： BEARD, Richard, L. , VULIGONDA, Vidyasagar , DUONG, Tien, T. , VU, Thong , DONELLO, John, E. , GARST, Michael, E. , RODRIGUES, Gerard, A.
IPC分类号： C07D401/12 , A61K31/517
CPC分类号： C07D401/12
摘要： A compound represented by the structural formula (I): Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
-
7.发明公开COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME 审中-公开随着对恢复选择性细胞色素P450RAI-1或选择性细胞色素P450RAI 2抑制效果和方法链接
公开(公告)号：EP1699775A2
公开(公告)日：2006-09-13
申请号：EP04815022.1
申请日：2004-12-17
申请人： ALLERGAN, INC.
发明人： VASUDEVAN, Jayasree , WANG, Liming , LIU, Xiaoxia , TSANG, Kwok, Yin , LI, Ling , TAKEUCHI, Janet, A. , VU, Thong , BEARD, Richard, L. , BHAT, Smita , VULIGONDA, Vidyasagar , CHANDRARATNA, Roshantha, A.
IPC分类号： C07D311/96 , C07D311/64 , C07D311/58 , C07C59/64 , C07C229/46 , C07C59/86 , C07C229/34 , C07C69/753 , C07C69/18 , C07C275/42 , C07C229/38 , C07C69/76
CPC分类号： C07C69/73 , C07C57/42 , C07C59/64 , C07C59/86 , C07C69/753 , C07C69/76 , C07C229/34 , C07C229/38 , C07C229/46 , C07C229/50 , C07C275/42 , C07C2601/02 , C07C2602/10 , C07D311/58 , C07D311/64 , C07D311/96
摘要： Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
摘要翻译： 在本说明书中提供特异性抑制或选择性地要么细胞色素P450RAI一种酶或细胞色素P450RAI 2酶式1至17的化合物。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.018 秒)
